Loading clinical trials...
Loading clinical trials...
A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Conditions
Interventions
Aldesleukin
Fludarabine
+3 more
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
May 16, 2024
Primary Completion Date
February 20, 2029
Completion Date
February 20, 2029
Last Updated
April 6, 2026
NCT04541381
NCT05468034
NCT03137095
NCT02600949
NCT07446322
NCT07547774
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions